Investment to support RNA therapeutics for epilepsy and neurological disorders Angelini Ventures has co-led a €20 million ...

Novartis has announced that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) achieved the primary ...

Kearney Urology Center has reported a 50% reduction in biopsies since adopting EpiSwitch PSE, a new accurate blood test for ...

M-Trust set to improve product safety and counterfeiting solutions Merck has launched the beta version of M-Trust, a ...

Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission has approved Rybrevant ...

Sequana Medical NV has announced the US FDA approval of its Alfapump system for treating recurrent or refractory ascites due to liver cirrhosis. This approval marks Alfapump as the first active ...

Patients don’t take their medicines because they don’t want to Debra is late getting up for work again. In her heart of hearts, she’s not really enjoying her job as a teaching assistant in the local ...

Matthew Taylor, chief executive of the NHS Confederation, stated, “This announcement sets out a range of welcome commitments – not just the commission but also short-term support for the sector as ...

MindMed has announced the dosing of the first patient in its phase 3 Voyage study of MM120 ODT, a pharmaceutically optimised form of lysergide D-tartrate (LSD) for treating Generalised Anxiety ...

Minoryx Therapeutics and Neuraxpharm Group have announced that leriglitazone has met the primary endpoint in the NEXUS trial for paediatric patients with cerebral adrenoleukodystrophy (cALD). The ...